SCHEMBL30444573

SCHEMBL30444573

CCCCCCCCCC(=O)NCc1csc(-c2ccccc2)n1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.61
HPGD P15428 3/20 0.55
ALDH1A1 P00352 1/20 0.55
GAA P10253 1/20 0.55
FAAH O00519 2/20 0.54
LMNA P02545 3/20 0.54
KDM4E B2RXH2 3/20 0.54
MAPT P10636 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
SUCNR1 Q9BXA5 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15338695 0.83 HPGD (0.55) HPGDALDH1A1GAALMNAKDM4E
SCHEMBL28958745 0.80 HPGD (0.56) HPGDALDH1A1LMNAKDM4EMAPT
SCHEMBL27482174 0.77 LMNA (0.58) HPGDALDH1A1LMNAKDM4EMAPT
SCHEMBL1683935 0.77 PLA2G4A (0.56) HPGDALDH1A1FAAHLMNAKDM4E
N-Benzyldodecanamide SCHEMBL3977374 0.77 EPHX2 (1.00) EPHX2HPGDALDH1A1GAAFAAH
SCHEMBL5696750 0.77 EPHX2 (1.00) EPHX2HPGDALDH1A1GAAFAAH
SCHEMBL16714726 0.77 EPHX2 (1.00) EPHX2HPGDALDH1A1GAAFAAH
SCHEMBL2524088 0.77 EPHX2 (1.00) EPHX2HPGDALDH1A1GAAFAAH
Nonanoic Acid Benzylamide SCHEMBL3280214 0.77 EPHX2 (1.00) EPHX2HPGDALDH1A1GAAFAAH
SCHEMBL5471650 0.77 EPHX2 (1.00) EPHX2HPGDALDH1A1GAAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230094176-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2023-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230094176-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC2, HDAC1 EPHX2 3208/4885HPGD 1445/4885ALDH1A1 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.